Judith M. Martin, MD
- Professor of Pediatrics
Martin earned her bachelor’s degree from the University of Pennsylvania, and then her MD from Icahn School of Medicine at Mount Sinai. She came to UPMC Children’s Hospital of Pittsburgh where she completed her training: a pediatric residency, one year as pediatric chief resident, followed by a fellowship in pediatric infectious diseases. She began her career at Children's as an instructor in the Division of Infectious Diseases, Department of Pediatrics, and one year later received a faculty appointment as an Assistant Professor. In 2006 she was promoted to associate professor; in 2013 she transferred from the Division of Infectious Diseases to the Division of General Academic Pediatrics, and in 2018, was promoted to professor of pediatrics.
Martin has been continuously funded since 1998, from sources such as the NIH, CDC, the American Heart Association, and industry groups. Her research investigates common infectious diseases in pediatric populations and the effectiveness of specific vaccines and treatments. She has conducted several longitudinal studies of group A streptococcal infections in school-aged children and is a nationally recognized expert in the management of Streptococcal pharyngitis. Other areas of clinical research studies include: management of acute otitis media, community-acquired pneumonia, urinary tract infections, and sinusitis. Martin has also participated in several surveillance studies of respiratory viral infections as well as numerous vaccine studies. These include recent studies of immunogenicity following influenza vaccination, a meningococcal vaccine in infants, and a monoclonal antibody study in infants. In addition, Martin has been the Director of the General Academic Pediatrics Clinical Trials Unit since 2016, having previously directed the Infectious Disease Clinical Trials Unit in the Division of Infectious Diseases. She leads a group of 6 physicians and over 20 staff members. The long-term goal of this research group is to improve the diagnosis and management of common pediatric infections that result in substantial utilization of health care resources.
Having long held an interest in the safe and ethical conduct of clinical research trials, Martin has held leadership positions in the university and the health system. She became a committee member for the Institutional Review Board at the University of Pittsburgh in 2007. Then, in 2013, she became vice-chair of two full review board committees in the Human Research Protection Office. Recently, she assumed additional duties as the Executive Vice-Chair.
Professional and Scientific Society Memberships
American Academy of Pediatrics (AAP), 1991-Present
Alpha Omega Alpha Medical Honor Society, 1994-Present
Infectious Disease Society of America, 1995-Present
Pediatric Infectious Disease Society, 1995-Present
The Lancefield Society, 1998-Present
The Society for Pediatric Research, 2004-Present
Public Responsibility in Medicine and Research (PRIM&R), 2014-Present
Education & Training
- AB, Philosophy, University of Pennsylvania, 1987
- MD, Icahn School of Medicine at Mount Sinai, 1991
- Residency in Pediatrics, UPMC Children's Hospital of Pittsburgh, 1991-1994
- Chief Pediatrics Resident, UPMC Children's Hospital of Pittsburgh, 1994-1995
- Fellowship in Pediatric Infectious Diseases, UPMC Children's Hospital of Pittsburgh, 1995-1998
- Certificate in Clinical Research, University of Pittsburgh School of Medicine and Graduate School of Public Health, 2002
Martin JM, Hoberman A, Barbadora KA, Shaikh N, Bhatnagar S, Shope T, Block SL, Haralam MA, Kurs-Lasky M, Green M. Changes Over Time in Nasopharyngeal Colonization in Children under 2 Years of Age at the Time of Diagnosis of Acute Otitis Media (1999-2014). Open Forum Infect Dis. 2018 Feb 17;5(3):ofy036. doi: 10.1093/ofid/ofy036. eCollection 2018 Mar.PMID:29588912
Martin JM, Avula R, Nowalk MP, Lin C, Horne WT, Chandran UR, Nagg JP, Zimmerman RK, Cole KS, Alcorn JF. Inflammatory Mediator Expression Associated with Antibody Response Induced by Live Attenuated Inactivated versus Inactivated Influenza Virus Vaccine in Children. Open Forum Infectious Diseases, Volume 5, Issue 11, 1 November 2018, ofy277, doi.org/10.1093/ofid/ofy277.
Martin JM, Simonian A, Muniz G, Green M, Shaikh N. Comparison of Bacterial Culture Results Obtained from Nasopharyngeal and Mid-turbinate Swabs in Children with Upper Respiratory Tract Infection Symptoms. Pediatr Infect Dis J. 2018 Nov;37(11) e275-7. doi: 10.1097/INF.0000000000002027
Shaikh N, Martin JM, Hoberman A, Skae M, Milkovich L, Nowalk A, McElheny C, Hickey RW, Kearney D, Majd M, Shalaby-Rana E, Tseng G, Alcorn JF, Kolls J, Kurs-Lasky M, Huo Z, Horne W, Lockhart G, Pohl H, Shope TR. Host and Bacterial Markers that Differ in Children with Cystitis and Pyelonephritis. J Pediatr. 2019 Mar 21. pii: S0022-3476(19)30027-7. doi: 10.1016/j.jpeds.2019.01.012
Lopez SMC, Martin JM, Johnson M, Kurs-Lasky M, Horne WT, Marshall CW, Cooper VS, Williams JV, Shaikh N. A method of processing nasopharyngeal swabs to enable multiple testing. Pediatr Res. 2019 Jul 9. doi: 10.1038/s41390-019-0498-1.
Shope TR, Walker BH, Aird L, Southward L, McCown JS, Martin JM. Influenza Vaccine Requirements in US Child Care Centers. J Pediatric Infect Dis Soc. 2019 Dec 12;. doi: 10.1093/jpids/piz078. PubMed PMID: 31828319.
Lewnard JA, Whittles JK, Rick AM, Martin JM. Naturally-acquired Immunity Against Group A Streptococcusin a Longitudinal Cohort Study. Clin Infect Dis. 2020 Jan 19;. doi: 10.1093/cid/ciaa044. PubMed PMID: 31955205.
Shaikh N, Martin JM, Hoberman A, Skae M, Milkovich L, McElheny C, Hickey RW, Gabriel LV, Kearney DH, Majd M, Shalaby-Rana E, Tseng G, Kolls J, Horne W, Huo Z, Shope TR. Biomarkers that differentiate false positive urinalyses from true urinary tract infection. Pediatr Nephrol. 2020 Feb;35(2):321-329. doi: 10.1007/s00467-019-04403-7. Epub 2019 Nov 22. PubMed PMID: 31758242; PubMed Central PMCID: PMC6942213..
Rick AM, Zaheer HA, Martin JM. Clinical Features of Group A Streptococcus in Symptomatic Children: Carriers versus Acute Infection. Pediatr Infect Dis J. 2020 June, 39(6):483-488.
Alcorn JF, Avula R, Chakka A, Nowalk MP, Lin C, Ortiz MA, Horne WT, Chandran UR, Nagg JP, Zimmerman RK, Cole KS, Moehling KK, Martin JM. Differential Gene Expression in Peripheral Blood Mononuclear Cells from Children Immunized with Inactivated Influenza Vaccine; Hum Vaccin Immunother. 2020 Apr 16:1-9. doi: 10.1080/21645515.2020.1711677. [Epub ahead of print] PMID:32298194.
Koenig L, Martin JM. Prescriptions for Community-acquired Pneumonia in Outpatient vs. Emergency Department Settings. Submitted to Ped Infect Dis J February 2020.
NIH 1U01IP001051-01, Enhanced Active Surveillance of Pediatric Respiratory Infections and Vaccine Preventable Diseases. (NVSN) (Site PI, 10% effort, PI: Williams), 2016-2021, $200,655 per year.
NIH 1U01IP001035-01, Immunological response to influenza vaccination in children and adolescents CORE: Influenza surveillance and vaccine effectiveness in a large diverse network (Site PI, 10% effort, PI: Zimmerman), 2014-2021, ADC $83,046.
NIH R01AI125642, Risk Stratification and Decision Support to Improve Care and Outcomes in Children with Pneumonia (Site PI, 10% effort, 2019-2021), $130,443.
Novus Therapeutics, A randomized, double-blind, placebo-controlled study to assess the safety and preliminary efficacy of OP-02, in addition to amoxicillin-clavulanate (A/C), in children 6 to 24 Months with Acute (Co-I, 10% effort, PI: Hoberman), 2018-2020, $1,798,448.
SRA0000017, Assessment of Otopathogens in Young Children with Acute Otitis Media (Co-I, 10% effort, PI: Hoberman), 2019-2021, $3,328,489.
Merck Outpatient Antimicrobial Stewardship, Outpatient Pediatric Antimicrobial Stewardship Program: Optimizing Antimicrobial Prescription Choices and De-labelling Drug Allergies in Community Offices (PI, 10% effort), 2020.
Medimmune Melody Study, A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Late Preterm and Term Infants (MELODY) (Site PI, 10% effort), 2019-2021.
GSK Bexsero, GlaxoSmithKline’s (GSK) Safety and Immunogenicity study of GSK Meningococcal Group B and 13 valent pneumococcal vaccines administered together with routine infant vaccines in healthy infants (Site PI, 10% effort), 2019-2023.
NIH, Vaccine Treatment and Evaluation Unit (VTUE) (Site PI, 10% effort), 2020-2026.